DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative biomedical surgical oncology products, today announced that its gamma radiation detection system product line, which includes the neo2000® and neoprobe® GDS systems, was featured in a peer reviewed publication characterizing the emergence of the use of radioactive “seeds” to assist in the surgical excision of non-palpable breast lesions. The procedure, termed radioactive seed localization (RSL), was indicated by the researchers to be a promising alternative to the standard wire-localized breast biopsy procedure. The research, published in the American Journal of Surgery, was conducted by research teams at the Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; and the University of South Florida, Tampa, FL.
